The fibroblast growth factor (FGF) family and its receptors (FGFRs) play a crucial role in angiogenesis, the process of new blood vessel formation, which is essential for both physiological and pathological conditions, including tumor growth. FGFs are heparin-binding growth factors that interact with various receptors, including tyrosine kinase receptors and heparan sulfate proteoglycans, to exert their pro-angiogenic effects. These effects are modulated by a variety of extracellular molecules and can be influenced by cross-talk with vascular endothelial growth factors (VEGFs) and inflammatory cytokines. FGFs are involved in tumor angiogenesis and vascularization, as evidenced by numerous experimental studies. FGFs exert their biological activities by binding to FGFRs on the surface of target cells. In vitro, FGFs induce a complex "pro-angiogenic phenotype" in endothelial cells, including proliferation, migration, protease production, integrin and cadherin receptor expression, and intercellular communication. FGF2, in particular, activates signaling pathways such as MAPK and PKC, which are essential for endothelial cell proliferation and migration. FGFs also modulate the expression of extracellular matrix components, integrins, and adhesion molecules, which are critical for endothelial cell migration and the formation of new blood vessels. In vivo, FGFs have been shown to promote angiogenesis in various experimental models, including the chick embryo CAM assay. The angiogenic activity of FGFs can be enhanced by interactions with other growth factors such as VEGF, and there is evidence of cross-talk between FGF and VEGF signaling pathways. FGF2 and VEGF can act synergistically to promote angiogenesis, although their roles in different contexts may vary. FGFs also interact with endothelial cell surface receptors, extracellular matrix components, and free molecules, which can influence their bioavailability and biological activity. Heparin and heparan sulfate proteoglycans (HSPGs) are important in FGF binding and signaling, with different HSPGs having distinct effects on FGF activity. Integrins, such as ανβ3, also play a role in FGF signaling and endothelial cell adhesion. Gangliosides, thrombospondin-1, fibstatin, and FGF-binding protein are other molecules that interact with FGFs and can modulate their activity. In the context of tumor angiogenesis, FGFs are involved in the formation and maintenance of tumor vasculature. Experimental studies have shown that FGF2 and other FGFs can promote tumor growth and angiogenesis, and their expression can be regulated by various factors. The interaction between FGFs and VEGF is complex, with both factors contributing to tumor vascularization. Targeting FGF signaling pathways has been shown to inhibit tumor growth and angiogenesis, highlighting the importanceThe fibroblast growth factor (FGF) family and its receptors (FGFRs) play a crucial role in angiogenesis, the process of new blood vessel formation, which is essential for both physiological and pathological conditions, including tumor growth. FGFs are heparin-binding growth factors that interact with various receptors, including tyrosine kinase receptors and heparan sulfate proteoglycans, to exert their pro-angiogenic effects. These effects are modulated by a variety of extracellular molecules and can be influenced by cross-talk with vascular endothelial growth factors (VEGFs) and inflammatory cytokines. FGFs are involved in tumor angiogenesis and vascularization, as evidenced by numerous experimental studies. FGFs exert their biological activities by binding to FGFRs on the surface of target cells. In vitro, FGFs induce a complex "pro-angiogenic phenotype" in endothelial cells, including proliferation, migration, protease production, integrin and cadherin receptor expression, and intercellular communication. FGF2, in particular, activates signaling pathways such as MAPK and PKC, which are essential for endothelial cell proliferation and migration. FGFs also modulate the expression of extracellular matrix components, integrins, and adhesion molecules, which are critical for endothelial cell migration and the formation of new blood vessels. In vivo, FGFs have been shown to promote angiogenesis in various experimental models, including the chick embryo CAM assay. The angiogenic activity of FGFs can be enhanced by interactions with other growth factors such as VEGF, and there is evidence of cross-talk between FGF and VEGF signaling pathways. FGF2 and VEGF can act synergistically to promote angiogenesis, although their roles in different contexts may vary. FGFs also interact with endothelial cell surface receptors, extracellular matrix components, and free molecules, which can influence their bioavailability and biological activity. Heparin and heparan sulfate proteoglycans (HSPGs) are important in FGF binding and signaling, with different HSPGs having distinct effects on FGF activity. Integrins, such as ανβ3, also play a role in FGF signaling and endothelial cell adhesion. Gangliosides, thrombospondin-1, fibstatin, and FGF-binding protein are other molecules that interact with FGFs and can modulate their activity. In the context of tumor angiogenesis, FGFs are involved in the formation and maintenance of tumor vasculature. Experimental studies have shown that FGF2 and other FGFs can promote tumor growth and angiogenesis, and their expression can be regulated by various factors. The interaction between FGFs and VEGF is complex, with both factors contributing to tumor vascularization. Targeting FGF signaling pathways has been shown to inhibit tumor growth and angiogenesis, highlighting the importance